As disruptors continue to push into the healthcare arena and pressure builds to cut drug prices, pharmaceutical companies are taking steps to remain competitive and enhance their drug pipelines.
Since Jan. 1, the following drugmakers announced or completed mergers, acquisitions, partnerships and general transactions.
Note: This is not an exhaustive list. Deals were reported by Becker's Hospital Review, beginning with the most recent.
1. Danaher buys GE's biopharmaceutical unit for $21.4B
Danaher Corp., a Fortune 500 science and technology conglomerate, will buy General Electric's biotechnology business for $21.4 billion in cash.
2. Roche strikes $4.8B deal to acquire Spark Therapeutics
Drug giant Roche will buy gene therapy developer Spark Therapeutics for about $4.8 billion in cash.
3. Merck to acquire Immune Design for $300M
Drugmaker Merck will acquire oncology company Immune Design for $300 million in cash.
4. J&J to buy robotic surgery startup Auris Health for $3.4B
Johnson & Johnson will shell out $3.4 billion in cash to buy robotic surgery company Auris Health.
5. Takeda finalizes Shire takeover, now among top 10 drugmakers worldwide
Takeda finalized its $62 billion acquisition of Shire Jan. 8, catapulting the Japanese company into a new league of pharma giants.
6. Eli Lilly buys Loxo Oncology for $8B
Eli Lilly plans to acquire Loxo Oncology for $8 billion in cash to expand its portfolio of cancer medications.
7. Bristol-Myers to buy Celgene for $74B
Bristol-Myers Squibb plans to acquire cancer drugmaker Celgene for $74 billion in cash and stock — one of the largest deals in pharmaceutical history.